
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne Inc. has demonstrated significant financial progress, achieving a gross margin of 53.0% in 2024, a substantial increase from 24.1% the previous year, alongside impressive revenue growth of 117% year-over-year during its first quarter as a public company, culminating in a positive net income of $1.5 million. The company reported substantial gains in its prenatal and oncology segments, with revenue increases of 102% year-over-year for prenatal tests, totaling $74.1 million, and an impressive 664% growth in oncology revenue, reaching $8.7 million. Given the strong market demand and anticipated increases in tests per patient, BillionToOne is positioned for significant future growth, with the potential for a 25%+ revenue compound annual growth rate (CAGR) in reproductive health, indicating a robust financial outlook.
Bears say
The financial outlook for BillionToOne Inc appears concerning due to significant risks related to the protection of its proprietary technology, as any failure to maintain its competitive advantage could weaken its market position. Additionally, potential decreases in reimbursements from Medicare and Medicaid, especially under the Clarifying Lawful Overseas Use of Data (PAMA) rates, may adversely impact future revenue streams, further stressing the company's financial stability. Reports of increased denial rates from payers regarding the efficacy of their tests could hinder expected revenue growth, particularly in the core prenatal testing segment and new oncology tests, thereby casting doubt on profitability moving forward.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares